VistaGen Therapeutics Inc... (VTGN)
Bid | 3.26 |
Market Cap | 103.39M |
Revenue (ttm) | 646K |
Net Income (ttm) | -55.78M |
EPS (ttm) | -1.79 |
PE Ratio (ttm) | -1.88 |
Forward PE | -2.12 |
Analyst | n/a |
Dividends | n/a |
Ask | 3.44 |
Volume | 345,634 |
Avg. Volume (20D) | 526,260 |
Open | 3.42 |
Previous Close | 3.47 |
Day's Range | 3.33 - 3.53 |
52-Week Range | 1.90 - 3.88 |
Beta | 0.55 |
Ex-Dividend Date | n/a |
About VTGN
undefined
Analysts project revenue of ... Unlock content with Pro Subscription

1 month ago · seekingalpha.com
Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call TranscriptVistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2026 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Joshua S. Prince - Chief...

1 month ago · fool.com
Vistagen (VTGN) Q1 R&D Expense Jumps 54%Vistagen (VTGN) Q1 R&D Expense Jumps 54%

2 months ago · businesswire.com
Vistagen to Present at the BTIG Virtual Biotechnology ConferenceSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...

2 months ago · businesswire.com
Vistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...

3 months ago · businesswire.com
Vistagen Appoints Elissa Cote as Chief Corporate Development OfficerSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...